CORRECTION

Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer

Michael D. Alvarado, MD¹, Elizabeth A. Mittendorf, MD², Mediget Teshome, MD², Alastair M. Thompson, MD², Richard J. Bold, MD³, Mark A. Gittleman, MD⁴, Peter D. Beitsch, MD⁵, Sarah L. Blair, MD⁶, Kaisa Kivilaid, MS⁷, Quentin J. Harmer, PhD⁸, and Kelly K. Hunt, MD²

¹Department of Surgery, University of California San Francisco, San Francisco, CA; ²Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; ³Division of Surgical Oncology, Department of Surgery, UC Davis Medical Center, Sacramento, CA; ⁴Breastcare Specialists, Allentown, PA; ⁵Dallas Surgical Group, Dallas, TX; ⁶Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, CA; ⁷Regulatory and Clinical Research Institute, Inc., Minneapolis, MN; ⁸Endomagnetics Limited, Cambridge, UK

CORRECTION TO:

ANN SURG ONCOL (2019) 26:3510–3516
[HTTPS://DOI.ORG/10.1245/S10434-019-07577-4](https://doi.org/10.1245/s10434-019-07577-4)

In the original article the authors' disclosures were incomplete. Following is the revised text:

This clinical study was sponsored by Endomagnetics Inc., which provided funding to the institutions of all authors (K. Hunt PI). Dr. Michael D. Alvarado received travel support from Endomagnetics Inc. All other authors reported no conflicts of interest.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1245/s10434-019-07577-4>.

© Society of Surgical Oncology 2020

Published Online: 8 June 2020

M. D. Alvarado, MD
e-mail: michael.alvarado@ucsf.edu